Excessive Pricing in Generic Drug Markets

Published date24 August 2017
Law FirmRopes & Gray LLP
AuthorRuchit Patel
Subject MatterEU,Prescription Drugs,Generic Drugs,Abuse of Dominance,Pfizer,Actavis Inc.,UK,Competition Authorities,Drug Pricing,UK Competition and Markets Authority (CMA),Pharmaceutical Industry

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT